Syndax Pharmaceuticals: USD 57 Price Target Meets Upcoming MAXPIRe Study Data
Reading Time: 3 minutes
Syndax Pharmaceuticals (SNDX) addresses niche markets for immuno-mediated diseases and oncology with currently rising revenues. Analysts at Citigroup confirmed the price target of USD 57 on September 29 and emphasized the potential of the drug Axatilimab for lung fibrosis. Management sees the company well-financed through the mechanism of action of its lead drug and positioned for upcoming study results. Specialization in immuno-mediated indications Syndax Pharmaceuticals (SNDX) focuses on the development and marketing of therapies for...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
